JUST IN | Sam Bankman-Fried sentenced to 25 years in prison for FTX fraud

Home

homevideos Newshealthcare NewsSun Pharma Q2 results preview: US business set to get a fillip from new drug launches

Sun Pharma Q2 results preview: US business set to get a fillip from new drug launches

Drug maker Sun Pharmaceutical Industries will report its second-quarter earnings later in the day and the street is expecting growth on-year basis .

By Ekta Batra Nov 13, 2018 8:43:19 AM IST (Updated)

Listen to the Article(6 Minutes)

Drug maker Sun Pharmaceutical Industries will report its second-quarter earnings later in the day and the street is expecting growth on-year basis .

It is not supposed to be a bad quarter for Sun Pharmaceutical Industries this time. In fact, the street expectations are that there will be a growth on year-on-year basis which will be led by a couple of their drug launches in the US.

They have had Yonsa which is from the specialty pipeline which they have launched in the US market plus they have the likes of Glumetza etc. so a lot of these drugs should contribute to the US business.

So revenue expected to grow 17 percent odd, margins are expected to come in at around 21 percent this quarter with a profit growth of around 14 percent odd.

CurrencyCommodities

Currency	Price	Change	%Change